DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
The $1 billion, part of a total of $4 billion in funding, will go toward detecting, diagnosing, tracing, monitoring, and mitigating COVID-19 infections.
The $1 billion, part of a total of $4 billion in funding, will go toward detecting, diagnosing, tracing, monitoring, and mitigating COVID-19 infections.
The $1 billion, part of a total of $4 billion in funding, will go toward detecting, diagnosing, tracing, monitoring, and mitigating COVID-19 infections.
